

1. Sales January to December 2008 and 2007

	2008	2007	% change	
	CHF m	CHF m	In CHF	In local currencies
January – December				
Pharmaceuticals Division	35,961	36,783	-2	+5
Roche Pharmaceuticals	22,164	22,970	-4	+3
Genentech	10,461	10,414	0	+11
Chugai	3,336	3,399	-2	-4
Diagnosics Division	9,656	9,350	+3	+10
Roche Group	45,617	46,133	-1	+6

2. Sales January to December 2008 and 2007 excluding Pandemic Tamiflu\*

	2008	2007	% change	
	CHF m	CHF m	In CHF	In local currencies
January – December				
Pharmaceuticals Division	35,724	34,927	+2	+10
Roche Pharmaceuticals	21,941	21,404	+3	+9
Genentech	10,461	10,414	0	+11
Chugai	3,322	3,109	+7	+4
Diagnosics Division	9,656	9,350	+3	+10
Roche Group	45,380	44,277	+2	+10

\* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

3. Quarterly local sales growth by Division in 2007 and 2008

	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007	Q4 2008 vs. Q4 2007
Pharmaceuticals Division	+1	+5	+8	+5
Roche Pharmaceuticals	+1	+3	+6	+2
Genentech	+9	+9	+14	+14
Chugai	-23	+2	-1	+5
Diagnostics Division	+9	+13	+11	+9
Roche Group	+2	+7	+9	+6

4. Quarterly local sales growth by Division in 2007 and 2008 excluding Pandemic Tamiflu\*

	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007	Q4 2008 vs. Q4 2007
Pharmaceuticals Division	+9	+10	+10	+9
Roche Pharmaceuticals	+11	+11	+8	+8
Genentech	+9	+9	+14	+14
Chugai	-2	+2	+10	+6
Diagnostics Division	+9	+13	+11	+9
Roche Group	+9	+10	+10	+9

\* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

5. Quarterly sales by Division in 2007 and 2008

CHF millions	Q4 2007	Q1 2008	Q2 2008	Q3 2008	Q4 2008
<b>Pharmaceuticals Division</b>	<b>9,659</b>	<b>8,568</b>	<b>8,689</b>	<b>8,936</b>	<b>9,768</b>
Roche Pharmaceuticals	6,178	5,498	5,440	5,485	5,741
Genentech	2,564	2,399	2,468	2,669	2,925
Chugai	917	671	781	782	1,102
<b>Diagnostics Division</b>	<b>2,527</b>	<b>2,287</b>	<b>2,460</b>	<b>2,365</b>	<b>2,544</b>
<b>Roche Group</b>	<b>12,186</b>	<b>10,855</b>	<b>11,149</b>	<b>11,301</b>	<b>12,312</b>

6. Quarterly sales by Division in 2007 and 2008 excluding Pandemic Tamiflu\*

CHF millions	Q4 2007	Q1 2008	Q2 2008	Q3 2008	Q4 2008
<b>Pharmaceuticals Division</b>	<b>9,201</b>	<b>8,523</b>	<b>8,639</b>	<b>8,900</b>	<b>9,662</b>
Roche Pharmaceuticals	5,736	5,455	5,390	5,449	5,647
Genentech	2,564	2,399	2,468	2,669	2,925
Chugai	901	669	781	782	1,090
<b>Diagnostics Division</b>	<b>2,527</b>	<b>2,287</b>	<b>2,460</b>	<b>2,365</b>	<b>2,544</b>
<b>Roche Group</b>	<b>11,728</b>	<b>10,810</b>	<b>11,099</b>	<b>11,265</b>	<b>12,206</b>

\* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

7. Top 20 Pharmaceuticals Division product sales<sup>1</sup> and local growth<sup>2</sup> in YTD December 2008: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	5,923	16%	2,930	14%	214	10%	2,779	19%
Avastin	5,207	37%	2,908	17%	210	476%	2,089	67%
Herceptin	5,092	12%	1,496	7%	249	47%	3,347	13%
CellCept	2,099	13%	1,026	15%	41	15%	1,032	11%
NeoRecormon/Epogin	1,774	-13%	-	-	470	-18%	1,304	-10%
Pegasys	1,635	6%	395	10%	102	54%	1,138	2%
Tarceva	1,215	23%	495	10%	47	2562%	673	27%
Xeloda	1,211	13%	428	9%	50	74%	733	14%
Bonviva/Boniva	1,108	35%	675	26%	-	-	433	55%
Lucentis	960	7%	960	7%	-	-	-	-
Tamiflu	609	-68%	430	-50%	88	-78%	91	-86%
Xolair	560	10%	560	10%	-	-	-	-
Valcyte/Cymevene	553	10%	258	7%	-	-	295	14%
Xenical	502	-13%	43	-40%	-	-	459	-9%
Pulmozyme	496	12%	278	15%	-	-	218	7%
Nutropin	413	-2%	401	-2%	-	-	12	-6%
Neutrogen	404	-3%	-	-	404	-3%	-	-
Rocephin	344	-10%	5	-74%	61	3%	278	-8%
Activase/TNKase	342	-1%	298	-2%	-	-	44	9%
Madopar	311	4%	-	-	20	4%	291	4%

<sup>1</sup> Roche Pharmaceuticals, Genentech and Chugai combined <sup>2</sup> versus YTD December 2007

8. Top 20 Pharmaceuticals Division quarterly local product sales growth<sup>1</sup> in 2007 and 2008

	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007	Q4 2008 vs. Q4 2007
MabThera/Rituxan	17%	16%	15%	16%
Avastin	35%	38%	37%	36%
Herceptin	11%	12%	14%	12%
CellCept	11%	16%	14%	11%
NeoRecormon/Epogin	-13%	-14%	-15%	-8%
Pegasys	-3%	10%	12%	5%
Tarceva	28%	27%	18%	19%
Xeloda	13%	14%	14%	12%
Bonviva/Boniva	56%	47%	26%	23%
Lucentis	-5%	2%	15%	19%
Tamiflu	-64%	-86%	-56%	-65%
Xolair	6%	7%	12%	13%
Valcyte/Cymevene	9%	10%	13%	9%
Xenical	-11%	-21%	-9%	-11%
Pulmozyme	15%	11%	6%	14%
Nutropin	-5%	-5%	1%	-1%
Neutrogen	1%	1%	0%	-13%
Rocephin	-4%	-13%	-16%	-6%
Activase/TNKase	-3%	-11%	-2%	13%
Madopar	0%	9%	4%	3%

<sup>1</sup> Roche Pharmaceuticals, Genentech and Chugai combined

9. Pharmaceuticals Division quarterly local product sales growth<sup>1</sup> US in 2007 and 2008

	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007	Q4 2008 vs. Q4 2007
MabThera/Rituxan	14%	13%	14%	15%
Avastin	13%	15%	18%	21%
Herceptin	9%	3%	15%	3%
CellCept	14%	15%	20%	12%
NeoRecormon/Epogin	-	-	-	-
Pegasys	-10%	5%	45%	9%
Tarceva	10%	17%	9%	5%
Xeloda	16%	5%	9%	8%
Bonviva/Boniva	47%	39%	16%	12%
Lucentis	-5%	2%	15%	19%
Tamiflu	83%	-87%	6%	-83%
Xolair	6%	7%	12%	13%
Valcyte/Cymevene	11%	5%	7%	5%
Xenical	-35%	-46%	-33%	-48%
Pulmozyme	10%	14%	13%	24%
Nutropin	-6%	-4%	1%	-1%
Neutrogen	-	-	-	-
Rocephin	-34%	-85%	-	-89%
Activase/TNKase	-6%	-12%	-2%	13%
Madopar	-	-	-	-

<sup>1</sup> Roche Pharmaceuticals and Genentech combined

10. Pharmaceuticals Division quarterly local product sales growth Japan<sup>1</sup> in 2007 and 2008

	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007	Q4 2008 vs. Q4 2007
MabThera/Rituxan	13%	11%	8%	9%
Avastin	-	1567%	442%	236%
Herceptin	16%	29%	69%	73%
CellCept	13%	21%	15%	10%
NeoRecormon/Epogin	-16%	-29%	-9%	-16%
Pegasys	98%	53%	49%	39%
Tarceva	-	-	-	699%
Xeloda	48%	73%	88%	81%
Bonviva/Boniva	-	-	-	-
Lucentis	-	-	-	-
Tamiflu	-93%	-78%	-98%	-2%
Xolair	-	-	-	-
Valcyte/Cymevene	-	-	-	-
Xenical	-	-	-	-
Pulmozyme	-	-	-	-
Nutropin	-	-	-	-
Neutrogen	1%	1%	0%	-13%
Rocephin	9%	-2%	-1%	5%
Activase/TNKase	-	-	-	-
Madopar	5%	5%	6%	0%

<sup>1</sup> Chugai

11. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World<sup>1</sup> in 2007 and 2008

	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007	Q4 2008 vs. Q4 2007
MabThera/Rituxan	21%	21%	17%	18%
Avastin	78%	78%	67%	52%
Herceptin	12%	15%	11%	13%
CellCept	8%	16%	9%	9%
NeoRecormon/Epogin	-13%	-7%	-17%	-4%
Pegasys	-4%	9%	1%	1%
Tarceva	40%	28%	17%	24%
Xeloda	11%	18%	14%	12%
Bonviva/Boniva	77%	61%	45%	47%
Lucentis	-	-	-	-
Tamiflu	-94%	-83%	-93%	6%
Xolair	-	-	-	-
Valcyte/Cymevene	8%	16%	19%	14%
Xenical	-7%	-17%	-6%	-7%
Pulmozyme	22%	8%	-3%	2%
Nutropin	-1%	-12%	-10%	-2%
Neutrogin	-	-	-	-
Rocephin	-3%	-9%	-13%	-6%
Activase/TNKase	30%	1%	1%	11%
Madopar	0%	9%	4%	4%

<sup>1</sup> Roche Pharmaceuticals

12. Top 20 Pharmaceuticals Division quarterly product sales<sup>1</sup> in 2007 and 2008

CHF millions	Q4 2007	Q1 2008	Q2 2008	Q3 2008	Q4 2008
MabThera/Rituxan	1,432	1,407	1,460	1,472	1,584
Avastin	1,135	1,131	1,220	1,351	1,505
Herceptin	1,261	1,225	1,249	1,295	1,323
CellCept	548	487	523	513	576
NeoRecormon/Epogin	510	442	450	427	455
Pegasys	447	369	416	405	445
Tarceva	288	286	301	298	330
Xeloda	312	281	292	307	331
Bonviva/Boniva	283	241	266	268	333
Lucentis	228	215	225	246	274
Tamiflu	512	278	49	101	181
Xolair	138	125	134	145	156
Valcyte/Cymevene	144	125	136	143	149
Xenical	142	136	128	126	112
Pulmozyme	128	117	120	120	139
Nutropin	113	97	98	106	112
Neutrogen	110	95	97	98	114
Rocephin	100	91	85	76	92
Activase/TNKase	88	83	81	81	97
Madopar	83	74	80	77	80

<sup>1</sup> Roche Pharmaceuticals, Genentech and Chugai combined

13. Pharmaceuticals Division quarterly product sales<sup>1</sup> in US in 2007 and 2008

CHF millions	Q4 2007	Q1 2008	Q2 2008	Q3 2008	Q4 2008
MabThera/Rituxan	709	675	706	732	817
Avastin	693	642	671	754	841
Herceptin	375	363	349	394	390
CellCept	290	215	243	247	321
NeoRecormon/Epogin	-	-	-	-	-
Pegasys	111	81	95	99	120
Tarceva	129	119	123	117	136
Xeloda	123	89	97	111	131
Bonviva/Boniva	190	153	159	155	208
Lucentis	228	215	225	246	274
Tamiflu	398	234	30	96	70
Xolair	138	125	134	145	156
Valcyte/Cymevene	73	54	62	66	76
Xenical	13	14	12	9	8
Pulmozyme	67	61	65	69	83
Nutropin	108	94	94	104	109
Neutrogen	-	-	-	-	-
Rocephin	1	3	1	0	1
Activase/TNKase	76	71	71	70	86
Madopar	-	-	-	-	-

<sup>1</sup> Roche Pharmaceuticals and Genentech combined

14. Pharmaceuticals Division quarterly product sales<sup>1</sup> in Japan in 2007 and 2008

CHF millions	Q4 2007	Q1 2008	Q2 2008	Q3 2008	Q4 2008
MabThera/Rituxan	55	43	52	51	68
Avastin	23	28	43	57	82
Herceptin	44	42	56	64	87
CellCept	10	8	11	9	13
NeoRecormon/Epogin	146	103	114	111	142
Pegasys	23	19	22	26	35
Tarceva	2	8	12	11	16
Xeloda	8	8	12	13	17
Bonviva/Boniva	-	-	-	-	-
Lucentis	-	-	-	-	-
Tamiflu	69	16	0	1	71
Xolair	-	-	-	-	-
Valcyte/Cymevene	-	-	-	-	-
Xenical	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Nutropin	-	-	-	-	-
Neutrogen	110	95	97	98	114
Rocephin	16	13	15	14	19
Activase/TNKase	-	-	-	-	-
Madopar	6	4	5	5	6

<sup>1</sup> Chugai

15. Pharmaceuticals Division quarterly product sales in Europe/Rest of World<sup>1</sup> in 2007 and 2008

CHF millions	Q4 2007	Q1 2008	Q2 2008	Q3 2008	Q4 2008
MabThera/Rituxan	668	689	702	689	699
Avastin	419	461	506	540	582
Herceptin	842	820	844	837	846
CellCept	248	264	269	257	242
NeoRecormon/Epogin	364	339	336	316	313
Pegasys	313	269	299	280	290
Tarceva	157	159	166	170	178
Xeloda	181	184	183	183	183
Bonviva/Boniva	93	88	107	113	125
Lucentis	-	-	-	-	-
Tamiflu	45	28	19	4	40
Xolair	-	-	-	-	-
Valcyte/Cymevene	71	71	74	77	73
Xenical	129	122	116	117	104
Pulmozyme	61	56	55	51	56
Nutropin	5	3	4	2	3
Neutrogen	-	-	-	-	-
Rocephin	83	75	69	62	72
Activase/TNKase	12	12	10	11	11
Madopar	77	70	75	72	74

<sup>1</sup> Roche Pharmaceuticals